Compare HTGC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTGC | NRIX |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | N/A | 2020 |
| Metric | HTGC | NRIX |
|---|---|---|
| Price | $16.10 | $23.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $18.86 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | ★ 12.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $5.24 | $48.05 |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $13.70 | $8.20 |
| 52 Week High | $19.67 | $25.09 |
| Indicator | HTGC | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 59.03 |
| Support Level | $15.17 | $14.63 |
| Resistance Level | $16.39 | $24.98 |
| Average True Range (ATR) | 0.28 | 1.23 |
| MACD | -0.02 | -0.26 |
| Stochastic Oscillator | 60.45 | 53.44 |
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.